Technical Data
B2553-06F
Bone Morphogenetic Protein 2, Recombinant, Human (BMP2, BMP-2, Bone Morphogenetic Protein 2A, BMP2A, BMP-2A)
2ug
Molecular Biology Storage: -20CShipping: Blue Ice
Source:
Recombinant corresponding to 115aa of human Bone Morphogenetic Protein -2 expressed in E.coli is a homodimeric, non-glycosylated, Polypeptide chain.

Molecular Weight:
~26kD

Biological Activity:
The ED50 as determined by the cytolysis of MC3T3-E1 cells is less then 50nug/ml

Dimers and Aggregates:
1% (SDS-PAGE)

Protein Content:
Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280nm using the absorbency value of 1.4 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a standard solution of BMP-2 as a Reference Standard.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
~26kD
Purity: ~95% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: 0.1ng/ug (IEU/ug)
Concentration: ~1mg/ml
Form: Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to 0.1mg/ml.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Histological analysis of a displaced femoral ring allograft spacer filled with a recombinant human bone morphogenetic protein-2-soaked collagen sponge. A case report. J Bone Joint Surg Am 2005 Oct;87(10):2318-22. 2. Expression of bone morphogenetic protein 2 in normal spontaneous labor at term, preterm labor, and preterm premature rupture of membranes. Am J Obstet Gynecol 2005 Sep;193(3 Pt 2):1137-43. 3. Recombinant human bone morphogenetic protein-2: a novel osteoinductive alternative to autogenous bone graft? Acta Orthop Belg 2005 Apr;71(2):133-48. 4. Murine spinal fusion induced by engineered mesenchymal stem cells that conditionally express bone morphogenetic protein-2. J Neurosurg Spine 2005 Jul;3(1):47-52. 5. Effects of immobilized recombinant human bone morphogenetic protein-2/succinylated type I atelocollagen on cellular activity of ST2 cells. J Biomed Mater Res A 2005 Oct 1;75(1):210-5. 6. Tissue engineering with recombinant human bone morphogenetic protein-2 for alveolar augmentation and oral implant osseointegration: experimental observations and clinical perspectives. Clin Implant Dent Relat Res 2005;7(2):112-9.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.